Nanosight, a member of the Nanotechnology Knowledge Transfer Network (NanoKTN), has secured its 250th sale and reached profitability for the first time since the company was established in 2005.
Nanosight's technology has been installed worldwide with users including BASF, Glaxosmithkline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever, together with many universities and research institutes.
UK-based Nanosight has developed a technique to view nanoparticles down to the size of several millionths of a millimetre.
This opens previously unimagined possibilities such as for the development of viral vaccines and drug-delivery systems, both of which require a great deal of precision.
The Nanosight technique measures on a particle-by-particle basis and so generates high-resolution particle-size distributions, allowing an accurate and precise measurement of virus or drug-delivery particle numbers and sizes.
This has clear implications for the manufacturing processes as well as helping to optimise product yield.
Since first joining NanoKTN for free, Nanosight has attended the network's events as both a speaker and exhibitor, using it as a means of securing business contacts within industry and academia.
By talking to industry professionals within the field and by meeting with academics from leading research institutions and universities, Nanosight has been able to increase its new business prospects as well as providing the company with a platform to deliver information about the benefits of its technology directly to its target audience.
According to the company, continued support from the NanoKTN's theme managers has enabled Nanosight to develop contact with key market professionals and generate new sales internationally.
Nanosight has grown rapidly and secured its position in the market as a manufacturer of nanoparticle characterisation technology, with more than 90 per cent of sales being outside the UK.
